# Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg

> **NCT00647816** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 100 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Propranolol Hydrochloride Extended-Release Capsules 160 mg
- **DRUG:** Inderal® LA Capsules 160 mg

## Key facts

- **NCT ID:** NCT00647816
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2005-09
- **Final completion:** 2005-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00647816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00647816, "Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00647816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*